Arcus Biosciences Announces Participation at Upcoming Investor Conference
13 Fevereiro 2019 - 7:10PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage
biopharmaceutical company focused on creating innovative cancer
immunotherapies, today announced that Terry Rosen, Ph.D., Chief
Executive Officer, will participate in a fireside chat at the 8th
Annual Leerink Partners Global Healthcare Conference on Wednesday,
February 27, 2019 at 11:30 am ET at the Lotte New York Palace, in
New York, NY.
To access the live audio webcast of the presentation, please
visit the “Events & Presentations” section of the Arcus website
at
https://investors.arcusbio.com/investors/events-and-presentations.
A replay of the webcast will be available for 30 days following the
live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company
focused on creating innovative cancer immunotherapies. Arcus
has several programs targeting important immuno-oncology pathways,
including a dual adenosine receptor antagonist AB928, which is in a
Phase 1/1b program to evaluate AB928 in combination with other
agents in multiple tumor types, and an anti-PD-1 antibody AB122,
which is being evaluated in a Phase 1 trial and is being tested in
combination with Arcus’s other product candidates. Arcus’s other
programs include AB154, an anti-TIGIT antibody, which is in a Phase
1 trial to evaluate AB154 as monotherapy and in combination with
AB122, and AB680, a small molecule inhibitor of CD73, which is in a
Phase 1 healthy volunteer study. Arcus has extensive in-house
expertise in medicinal chemistry, immunology, biochemistry,
pharmacology and structural biology. For more information about
Arcus Biosciences, please visit www.arcusbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190213005671/en/
Nicole Arndt(510) 284-4728narndt@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024